Novel HMGB1-inhibiting therapeutic agents for experimental sepsis.
Sepsis refers to a systemic inflammatory response syndrome resulting from a microbial infection. The inflammatory response is partly mediated by innate immune cells (such as macrophages, monocytes, and neutrophils), which not only ingest and eliminate invading pathogens but also initiate an inflammatory response by producing early (e.g., TNF and IFN-gamma) and late (e.g., high-mobility group box [HMGB1]) proinflammatory cytokines. Here, we briefly review emerging evidence that support extracellular HMGB1 as a late mediator of experimental sepsis and discuss therapeutic potential of several HMGB1-inhibiting agents (including neutralizing antibodies and steroid-like tanshinones) in experimental sepsis.
Wang
Haichao
H
The Feinstein Institute for Medical Research, North Shore-LIJ Health System, Community Drive, Manhasset, NY 11030, USA. hwang@nshs.edu
Ward
Mary F
MF
Sama
Andrew E
AE